Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.

Front Oncol · 2021 · PMC8414886 · PMID 34485111

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an evident trendno p-value reported

There was an evident trend to favor PARPi combination therapy over monotherapy in BRCA-mutated women (HR: 0.29, 95% CI: 0.19 to 0.45), while there was no significant difference in women with wild-type or unknown BRCA status (HR: 0.69, 95% CI: 0.46 to 1.04).

also in 268 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.